We are live on !
Find out more
HighMark Wealth Management Portfolio holdings
AUM
$299M
Turnover
13.67%
1-Year Est. Return
53.01%
This Fund
S&P 500
This Quarter Est. Return
+21.77%
1 Year Est. Return
+53.01%
3 Year Est. Return
+109.68%
5 Year Est. Return
+113.63%
10 Year Est. Return
–
AUM
$299M
AUM Growth
+$52.9M
(+22%)
Cap. Flow
+$8.26M
Cap. Flow % of AUM
Cap. Flow %
2.77%
Top 10 Holdings %
Top 10 Hldgs %
65.82%
Holding
600
New
46
Increased
156
Reduced
94
Closed
36
Avg Time Held
Equity + Options
3.4
years
Top 10 Avg Time Held
Equity + Options
2.7
years
Top 20 Avg Time Held
Equity + Options
2.3
years
Avg Time Held Equity only
3.4
years
Top 10 Avg Time Held Equity only
2.7
years
Top 20 Avg Time Held Equity only
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Health Care Index ETF
FHLC
|
+$18.3M |
| 2 |
SI-BONE Inc
SIBN
|
+$3.79M |
| 3 |
Duos Technologies
DUOT
|
+$2.91M |
| 4 |
Apogee Therapeutics
APGE
|
+$2.91M |
| 5 |
Neuropace
NPCE
|
+$1.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$9.41M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$5.14M |
| 3 |
AnaptysBio
ANAB
|
+$3.29M |
| 4 |
iShares MSCI EAFE Value ETF
EFV
|
+$1.64M |
| 5 |
Piper Sandler
PIPR
|
+$1.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 64.9% |
| 2 | Healthcare | 21.84% |
| 3 | Technology | 4.77% |
| 4 | Financials | 3.58% |
| 5 | Industrials | 1.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
West Pharmaceutical
WST
$27.7B
| $151K | 0.05% |
420
| – | – |
2023 Q1
13 quarters
|
|
102
Janus Henderson AAA CLO ETF
JAAA
$32.1B
| $146K | 0.05% |
+2,900
| New | +$147K |
2026 Q2
0 quarters
|
|
103
CVS Health
CVS
$121B
| $142K | 0.05% |
1,374
+11
| +0.8% | +$982 |
2019 Q4
26 quarters
|
|
104
RB Global
RBA
$15.6B
| $140K | 0.05% |
1,205
| – | – |
2023 Q1
13 quarters
|
|
105
PepsiCo
PEP
$189B
| $140K | 0.05% |
1,034
+7
| +0.7% | +$1.05K |
2019 Q4
26 quarters
|
|
106
iShares MSCI ACWI ETF
ACWI
$32.4B
| $140K | 0.05% |
890
+5
| +0.6% | +$764 |
2019 Q4
26 quarters
|
|
107
Vanguard Total International Stock ETF
VXUS
$159B
| $138K | 0.05% |
1,612
-438
| -21% | -$36.7K |
2024 Q3
7 quarters
|
|
108
Walt Disney
DIS
$195B
| $138K | 0.05% |
1,432
+124
| +9% | +$12.6K |
2019 Q4
26 quarters
|
|
109
Advanced Micro Devices
AMD
$829B
| $137K | 0.05% |
236
+65
| +38% | +$26.6K |
2019 Q4
26 quarters
|
|
|
VFL
110
DELISTED
abrdn National Municipal Income Fund
VFL
| $134K | 0.04% |
12,880
| – | – |
2022 Q1
17 quarters
|
|
111
DexCom
DXCM
$29.6B
| $127K | 0.04% |
1,888
-960
| -34% | -$64K |
2019 Q4
26 quarters
|
|
112
Valero Energy
VLO
$123B
| $124K | 0.04% |
475
-125
| -21% | -$30.8K |
2019 Q4
26 quarters
|
|
113
S&P Global
SPGI
$134B
| $122K | 0.04% |
300
| – | – |
2023 Q1
13 quarters
|
|
114
Medtronic
MDT
$124B
| $120K | 0.04% |
1,536
+139
| +10% | +$11.2K |
2019 Q4
26 quarters
|
|
115
AT&T
T
$153B
| $115K | 0.04% |
5,566
+2,922
| +111% | +$72.5K |
2019 Q4
26 quarters
|
|
116
Huntington Bancshares
HBAN
$31.6B
| $114K | 0.04% |
6,434
+57
| +0.9% | +$941 |
2021 Q2
20 quarters
|
|
117
Intel
INTC
$452B
| $107K | 0.04% |
769
-72
| -9% | -$7.28K |
2025 Q1
5 quarters
|
|
118
Danaher
DHR
$162B
| $107K | 0.04% |
560
| – | – |
2023 Q1
13 quarters
|
|
119
Nokia
NOK
$44.1B
| $106K | 0.04% |
8,004
| – | – |
2025 Q2
4 quarters
|
|
120
Pfizer
PFE
$173B
| $105K | 0.04% |
4,377
+32
| +0.7% | +$837 |
2019 Q4
26 quarters
|
|
121
Idexx Laboratories
IDXX
$44.6B
| $105K | 0.04% |
199
| – | – |
2023 Q1
13 quarters
|
|
122
iShares Biotechnology ETF
IBB
$10.8B
| $104K | 0.03% |
547
| – | – |
2019 Q4
26 quarters
|
|
123
State Street Energy Select Sector SPDR ETF
XLE
$45.4B
| $104K | 0.03% |
1,958
+3
| +0.2% | +$172 |
2019 Q4
26 quarters
|
|
124
Marriott International
MAR
$103B
| $102K | 0.03% |
275
+16
| +6% | +$5.9K |
2022 Q1
17 quarters
|
|
125
Chevron
CVX
$445B
| $100K | 0.03% |
605
+32
| +6% | +$5.96K |
2019 Q4
26 quarters
|
|
Similar funds
HighMark Wealth Management's Q2 2026 Portfolio in Review
As of Q2 2026, HighMark Wealth Management held 600 positions worth $299M, up 22% from $246M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
HighMark Wealth Management's Q2 2026 filing shows 46 new, 156 increased, 94 reduced and 36 closed positions. Its largest new stake was Duos Technologies: 289,884 shares worth $3.48M. The largest sale was Centessa Pharmaceuticals, an estimated $9.41M.
By sector, the portfolio is most concentrated in Miscellaneous at 65% of assets, down from 65% a quarter earlier, followed by Healthcare and Technology.
- HighMark Wealth Management's largest Q2 2026 buy was Duos Technologies: 289,884 shares worth $3.48M.
- HighMark Wealth Management added most to Fidelity MSCI Health Care Index ETF in Q2 2026, an estimated $18.3M increase.
- HighMark Wealth Management's biggest Q2 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $5.14M.
- HighMark Wealth Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $9.41M.
- HighMark Wealth Management's ten largest holdings make up 66% of its $299M portfolio in Q2 2026.
- HighMark Wealth Management opened 46 new positions and closed 36 in Q2 2026.
- HighMark Wealth Management's portfolio value rose 22% quarter-over-quarter to $299M.
Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.